Developer docs
API playgroundTry for free, no card

Search company profiles

Xvivo Perfusion

Full company profile

uuid0007yos

Namestring
Xvivo Perfusion
Legal namestring
Xvivo Perfusion AB (publ)
Company typeenum
Public
Founded yearint
1998
Descriptiontext

Xvivo Perfusion AB (publ) is a Sweden-based publicly traded medtech company (OTCMKTS: XVIPY), founded in 1998 and headquartered in Gothenburg, that develops ex vivo organ perfusion and preservation technology for use in transplantation. The company's core offering consists of machine perfusion systems for donor lungs, hearts, kidneys, and livers; single-use disposables and consumables required for each procedure; and a CE-marked organ storage device. Its clinical value proposition centers on enabling transplant centers and organ procurement organizations (OPOs) to assess, preserve, and rehabilitate marginal donor organs that would otherwise be rejected — for example, lungs initially declined by multiple transplant centers were successfully transplanted after nearly five hours of machine perfusion at Indiana Donor Network in January 2026.

The company generates revenue through three streams: capital equipment sales of perfusion machines, recurring procedure-based revenue from single-use disposables, and professional services including education, training, and technical support. Go-to-market is enterprise field sales directed at transplant centers and OPOs in Europe (Sweden, Italy via the XVIVO S.r.l. subsidiary) and the United States (via the Star Teams Inc. subsidiary). Pricing is quote-based and not publicly disclosed. Strategic positioning is reinforced by recent M&A: Star Teams Inc. (US organ recovery services, acquired November 2021 for USD 12.61M plus earn-out up to USD 13.75M) and XVIVO S.r.l. (Italian distributor with CE-marked organ storage device, acquired November 2022 for up to EUR 12.0M plus EUR 2.4M earn-out). The company is currently scaling beyond its lung franchise, with planned 2026 launches in heart, kidney, and liver categories in the U.S. market under a reorganized executive structure that elevates U.S. strategy and business development.

Short descriptiontext

Xvivo Perfusion AB is a Sweden-based publicly traded medtech company that develops ex vivo organ perfusion machines, disposables, and CE-marked storage devices for transplant centers and organ procurement organizations, enabling use of marginal donor lungs, hearts, kidneys, and livers across Europe and the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMölndal, Sweden
HQ citystring
Mölndal
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
organ perfusion systems, organ preservation devices, transplant medical devices, perfusion consumables, ex vivo organ storage
Industry2 codes
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAIAF
Infusion Pumps (Ambulatory/Stationary)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code3 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Pumps & Pumping Equipment3561
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Organ Perfusion and Transplant Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Perfusion Machines and Systems
TypeHardware Sales
Description

Sale of machine perfusion devices and systems used for organ preservation and assessment. Revenue derived from capital equipment sales to transplant centers and organ recovery organizations.

einpresswire.com
2Disposables and Consumables
TypeUsage Based
Description

Recurring revenue from single-use disposables and consumables required for organ perfusion procedures, providing recurring revenue streams tied to transplant volume.

biospace.com
3Service and Support
TypeProfessional Services
Description

Education, training, and technical support services for perfusion equipment, including service contracts and on-site support for organ recovery operations.

xvivogroup.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Xvivo Perfusion develops, manufactures, and sells ex vivo organ perfusion machines, single-use disposables, and CE-marked organ storage devices used by transplant centers and organ procurement organizations to preserve, assess, and recondition donor organs (lungs, heart, kidney, liver) before transplantation. The portfolio is complemented by organ recovery services (Star Teams in the US), CE-marked storage devices (via XVIVO S.r.l. in Italy), and education, training, and technical support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Enables successful transplantation of lungs initially rejected by multiple regional transplant centers
+1 more record
Product overview1 text field

Xvivo Perfusion is a medtech company specializing in ex vivo organ perfusion technology for organ transplantation. The company's portfolio consists of perfusion machines (for lungs, heart, kidney, and liver), single-use perfusion disposables, and CE-marked organ storage devices. The product architecture centers on a core perfusion platform supported by consumable disposables. The company has expanded through acquisitions including Star Teams Inc. (US organ recovery services, 2021) and XVIVO S.r.l. (Italian distributor with CE-marked storage device, 2022). Upcoming product launches are planned in heart, kidney, and liver categories, with the company pioneering in-house machine perfusion capabilities for organ recovery organizations.

Product and service5 records
1In-House Lung Machine Perfusion System
CategoryOrgan Perfusion Equipment
Description

Machine perfusion system enabling organ recovery organizations to perform in-house perfusion of marginal donor lungs, improving organ function before transplantation. Developed for use by OPOs and recovery teams.

2Organ Perfusion Machines
CategoryOrgan Perfusion Equipment
Description

Ex vivo perfusion machines used for preservation and reconditioning of donor organs across multiple organ types including lungs, heart, kidney, and liver. Enable organ viability assessment and preservation between donation and transplantation. Sold to transplant centers and organ recovery organizations.

3Perfusion Disposables
CategoryPerfusion Consumables
Description

Single-use consumables required for organ perfusion procedures, including tubing sets, cannulas, and preservation solutions used with Xvivo's perfusion machines. Generates recurring revenue tied to transplant procedure volume.

4CE-Marked Organ Storage Device
CategoryOrgan Preservation Devices
Description

CE-marked medical device for ex vivo organ storage and transport during the transplantation process. Part of the perfusion machine portfolio acquired through the Avionord transaction, enhancing service offerings in the European market.

5Star Teams Organ Recovery Services
CategoryOrgan Recovery Services
Description

US organ recovery services provided by Star Teams Inc., acquired in November 2021. Complements Xvivo's perfusion technology portfolio by delivering organ recovery expertise to US transplant centers and OPOs.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Partnership with Indiana Donor Network for deployment of in-house machine perfusion system for marginal lungs. Indiana Donor Network became the first U.S. organ recovery organization with in-house lung perfusion capability, enabling successful transplantation of lungs initially rejected by multiple transplant centers. This partnership positions the collaboration to enable further lifesaving transplants from previously rejected organs.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-29
Description

Wisconsin-based partnership for machine perfusion technology deployment. Perfusion Solution collaborated with XVIVO and Indiana Donor Network on the first U.S. in-house machine perfusion system for marginal lungs, contributing to the successful transplant in Indiana on January 29, 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Xvivo Perfusion

Organ Perfusion and Transplant Medical Devicesxvivoperfusion.com

Xvivo Perfusion AB is a Sweden-based publicly traded medtech company that develops ex vivo organ perfusion machines, disposables, and CE-marked storage devices for transplant centers and organ procurement organizations, enabling use of marginal donor lungs, hearts, kidneys, and livers across Europe and the United States.

What Xvivo Perfusion does

Xvivo Perfusion AB (publ) is a Sweden-based publicly traded medtech company (OTCMKTS: XVIPY), founded in 1998 and headquartered in Gothenburg, that develops ex vivo organ perfusion and preservation technology for use in transplantation. The company's core offering consists of machine perfusion systems for donor lungs, hearts, kidneys, and livers; single-use disposables and consumables required for each procedure; and a CE-marked organ storage device. Its clinical value proposition centers on enabling transplant centers and organ procurement organizations (OPOs) to assess, preserve, and rehabilitate marginal donor organs that would otherwise be rejected — for example, lungs initially declined by multiple transplant centers were successfully transplanted after nearly five hours of machine perfusion at Indiana Donor Network in January 2026.

The company generates revenue through three streams: capital equipment sales of perfusion machines, recurring procedure-based revenue from single-use disposables, and professional services including education, training, and technical support. Go-to-market is enterprise field sales directed at transplant centers and OPOs in Europe (Sweden, Italy via the XVIVO S.r.l. subsidiary) and the United States (via the Star Teams Inc. subsidiary). Pricing is quote-based and not publicly disclosed. Strategic positioning is reinforced by recent M&A: Star Teams Inc. (US organ recovery services, acquired November 2021 for USD 12.61M plus earn-out up to USD 13.75M) and XVIVO S.r.l. (Italian distributor with CE-marked organ storage device, acquired November 2022 for up to EUR 12.0M plus EUR 2.4M earn-out). The company is currently scaling beyond its lung franchise, with planned 2026 launches in heart, kidney, and liver categories in the U.S. market under a reorganized executive structure that elevates U.S. strategy and business development.

Xvivo Perfusion firmographics

Firmographics
Name
Xvivo Perfusion
Legal name
Xvivo Perfusion AB (publ)
Website
https://xvivoperfusion.com
Company type
Public
Founded year
1998
Operating status
Operating
Headcount range
51–100 employees
Short description
Xvivo Perfusion AB is a Sweden-based publicly traded medtech company that develops ex vivo organ perfusion machines, disposables, and CE-marked storage devices for transplant centers and organ procurement organizations, enabling use of marginal donor lungs, hearts, kidneys, and livers across Europe and the United States.
Ownership category
akta.pro rank

Xvivo Perfusion industry classification

Industry
Product category
Organ Perfusion and Transplant Medical Devices
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Pumps & Pumping Equipment (3561), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHAFAG
Mechanical Circulatory Support (VAD, IABP, ECMO)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAIAF
Infusion Pumps (Ambulatory/Stationary)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Organ perfusion systems
  • Organ preservation devices
  • Transplant medical devices
  • Perfusion consumables
  • Ex vivo organ storage

Where Xvivo Perfusion is headquartered

Location

Headquarters

HQ city
Mölndal
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Xvivo Perfusion business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Perfusion Machines and Systems: Sale of machine perfusion devices and systems used for organ preservation and assessment. Revenue derived from capital equipment sales to transplant centers and organ recovery organizations.
  2. Disposables and Consumables: Recurring revenue from single-use disposables and consumables required for organ perfusion procedures, providing recurring revenue streams tied to transplant volume.
  3. Service and Support: Education, training, and technical support services for perfusion equipment, including service contracts and on-site support for organ recovery operations.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Xvivo Perfusion product offering

Product offering

Core offering

Xvivo Perfusion develops, manufactures, and sells ex vivo organ perfusion machines, single-use disposables, and CE-marked organ storage devices used by transplant centers and organ procurement organizations to preserve, assess, and recondition donor organs (lungs, heart, kidney, liver) before transplantation. The portfolio is complemented by organ recovery services (Star Teams in the US), CE-marked storage devices (via XVIVO S.r.l. in Italy), and education, training, and technical support.

Product overview

Xvivo Perfusion is a medtech company specializing in ex vivo organ perfusion technology for organ transplantation. The company's portfolio consists of perfusion machines (for lungs, heart, kidney, and liver), single-use perfusion disposables, and CE-marked organ storage devices. The product architecture centers on a core perfusion platform supported by consumable disposables. The company has expanded through acquisitions including Star Teams Inc. (US organ recovery services, 2021) and XVIVO S.r.l. (Italian distributor with CE-marked storage device, 2022). Upcoming product launches are planned in heart, kidney, and liver categories, with the company pioneering in-house machine perfusion capabilities for organ recovery organizations.

Differentiator

Problem solved

Functional benefit

Products and services

  • In-House Lung Machine Perfusion System Machine perfusion system enabling organ recovery organizations to perform in-house perfusion of marginal donor lungs, improving organ function before transplantation. Developed for use by OPOs and recovery teams.
  • Organ Perfusion Machines Ex vivo perfusion machines used for preservation and reconditioning of donor organs across multiple organ types including lungs, heart, kidney, and liver. Enable organ viability assessment and preservation between donation and transplantation. Sold to transplant centers and organ recovery organizations.
  • Perfusion Disposables Single-use consumables required for organ perfusion procedures, including tubing sets, cannulas, and preservation solutions used with Xvivo's perfusion machines. Generates recurring revenue tied to transplant procedure volume.
  • CE-Marked Organ Storage Device CE-marked medical device for ex vivo organ storage and transport during the transplantation process. Part of the perfusion machine portfolio acquired through the Avionord transaction, enhancing service offerings in the European market.
  • Star Teams Organ Recovery Services US organ recovery services provided by Star Teams Inc., acquired in November 2021. Complements Xvivo's perfusion technology portfolio by delivering organ recovery expertise to US transplant centers and OPOs.

Quantifiable outcome

  • Enables successful transplantation of lungs initially rejected by multiple regional transplant centers
  • +1 more outcomes

Companies that use Xvivo Perfusion

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Xvivo Perfusion technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Xvivo Perfusion partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • Indiana Donor NetworkcoreStrategic or Co-development Partner · 29 January 2026Partnership with Indiana Donor Network for deployment of in-house machine perfusion system for marginal lungs. Indiana Donor Network became the first U.S. organ recovery organization with in-house lung perfusion capability, enabling successful transplantation of lungs initially rejected by multiple transplant centers. This partnership positions the collaboration to enable further lifesaving transplants from previously rejected organs.
  • Perfusion SolutionminorStrategic or Co-development Partner · 29 January 2026Wisconsin-based partnership for machine perfusion technology deployment. Perfusion Solution collaborated with XVIVO and Indiana Donor Network on the first U.S. in-house machine perfusion system for marginal lungs, contributing to the successful transplant in Indiana on January 29, 2026.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Xvivo Perfusion competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Xvivo Perfusion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Xvivo Perfusion leadership team

Management profile

Number of profiles

Profiles3 records

Xvivo Perfusion subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Xvivo Perfusion funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Xvivo Perfusion M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xvivo Perfusion

What does Xvivo Perfusion do?

Xvivo Perfusion develops, manufactures, and sells ex vivo organ perfusion machines, single-use disposables, and CE-marked organ storage devices used by transplant centers and organ procurement organizations to preserve, assess, and recondition donor organs (lungs, heart, kidney, liver) before transplantation. The portfolio is complemented by organ recovery services (Star Teams in the US), CE-marked storage devices (via XVIVO S.r.l. in Italy), and education, training, and technical support.

Is Xvivo Perfusion a public or private company?

Xvivo Perfusion is a public company. It is classified as public and is currently operating.

When was Xvivo Perfusion founded?

Xvivo Perfusion was founded in 1998. It employs 51 to 100 people.

Where is Xvivo Perfusion based?

Xvivo Perfusion is headquartered in Mölndal, Sweden, in the Europe region.

How does Xvivo Perfusion make money?

Three revenue lines are on record. Perfusion Machines and Systems are the primary driver. The others are disposables and Consumables and service and Support.

Does Xvivo Perfusion have an API?

No public API is recorded for Xvivo Perfusion.

What industry is Xvivo Perfusion in?

Xvivo Perfusion's product category is Organ Perfusion and Transplant Medical Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAHAIAF, Infusion Pumps (Ambulatory/Stationary). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaXvivo Perfusion AB (publ) (XVIPY) Q3 2026 Earnings Call TranscriptXvivo Perfusion reported Q3 2026 sales in line with the first half of the year, with organic growth of 32% compared to Q3 2025. EBITDA remained strong, supporting healthy operating cash flow, and total cash flow was close to neutral for the fourth consecutive quarter. The lung market continued to show strong growth.The future of tradingXVIVO Perfusion announces 2027 annual general meetingXVIVO Perfusion will hold its annual general meeting on April 27, 2027 in Gothenburg. Shareholders will vote on the meeting chair, board size, board elections, board remuneration, auditor remuneration, and any proposed changes to the nomination committee appointment procedure.MarketScreenerFDA accepts Xvivo Perfusion's application for heart transport systemThe FDA accepted Xvivo Perfusion's PMA application for its heart transport system, which uses hypothermic oxygenated perfusion. The application is supported by data from the PRESERVE IDE study with 141 patients at 14 U.S. centers, and the system also received CE certification in Europe.The future of tradingXVIVO says FDA accepts PMA filing for Heart Assist Transport SystemXvivo Perfusion filed a Premarket Approval application with the FDA for its XVIVO Heart Assist Transport System, backed by clinical data from the PRESERVE IDE trial of 141 patients. The device uses hypothermic oxygenated perfusion for extended-criteria donor hearts, and the FDA authorized up to 120 patients in a continued access protocol during review.The future of tradingXVIVO Perfusion AB: XVIVO announces FDA receipt of PMA application for the XVIVO Heart Assist Transport SystemXVIVO announced the FDA received a PMA application for its Heart Assist Transport System, supported by PRESERVE IDE trial data from 141 patients and additional evidence. The system uses Hypothermic Oxygenated Perfusion to preserve donor hearts. XVIVO expects the PMA review to take about 18 months.MarketScreenerHandelsbanken Adds Xvivo and Vimian as Sector Favorites, Drops Danish DuoHandelsbanken added Xvivo and Vimian to its healthcare sector favorites list, removing Genmab and Novo Nordisk. The bank cites Xvivo's upcoming product launches and Vimian's 10% organic sales growth as catalysts. The updated list includes 18 companies, with Xvivo and Vimian now included.Dagens industriXvivos vd: Fler kan överleva till en lägre kostnadXvivo Perfusion, a Swedish transplantation company, has received CE certification for its heart preservation technology, enabling commercial availability across the European market. The company's CEO states that the technology can help more patients survive at a lower cost. This regulatory approval marks the company's expansion of its organ preservation portfolio into the European Union.Dagens industriBure-ägt bolag rusar efter ”regulatorisk milstolpe”Xvivo Perfusion, a company owned by Bure Ventures, has received CE certification for its heart preservation technology, allowing the system to be made available across Europe. This regulatory milestone has driven a significant rise in the company's stock price on the exchange.MarketScreenerXvivo Perfusion gets clearance to enroll more patients in US heart studyXvivo Perfusion AB, a Sweden-based medical technology company, has received regulatory clearance to enroll additional patients in a US-based clinical study related to heart preservation or perfusion technology. The company specializes in organ, tissue, and cell preservation solutions for transplantation, operating in segments covering durable medical equipment and non-durable products and services. The expansion of enrollment in the US heart study represents a clinical milestone for the company's technology platform.AInvestXVivo Perfusion AB: Stifel cuts target price to SEK 353 from SEK 362Stifel has lowered its target price for XVivo Perfusion AB (XVIVO.ST) to SEK 353 from SEK 362, while maintaining its buy recommendation on the stock. The adjustment reflects updated financial models and market conditions, though no significant changes to the company's fundamentals have been indicated. XVivo Perfusion is a leader in medical technologies for organ preservation and perfusion.